Research programme: kinase inhibitors - Locus

Drug Profile

Research programme: kinase inhibitors - Locus

Alternative Names: LP-1890; LP-590

Latest Information Update: 01 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Locus Pharmaceuticals
  • Class Ethers; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors; Proto oncogene protein c ret inhibitors; Raf kinase inhibitors; TIE 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Inflammation

Most Recent Events

  • 20 Aug 2009 Preclinical trials in Autoimmune disorders in USA (PO)
  • 20 Aug 2009 Preclinical trials in Inflammation in USA (PO)
  • 20 Aug 2009 Preclinical pharmacokinetics data presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top